Radioligand dissociation measurements: Potential interference of rebinding and allosteric mechanisms and physiological relevance of the biological model systems

Expert Opinion on Drug Discovery

Volumn 7, Issue 7, 2012, Pages 583-595

  Vauquelin, Georges ^a   Van Liefde, Isabelle ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Allosteric modulation; Avidity; Bivalent ligand; Cell lines; Diffusion; Drug target; Radioligand; Rebinding; Receptors; Residence time

Indexed keywords

EPITOPE; RADIOLIGAND;

ALLOSTERISM; BINDING AFFINITY; CULTURE MEDIUM; DIFFUSION; DRUG LABELING; DRUG RECEPTOR BINDING; DRUG TARGETING; LIGAND BINDING; PHARMACODYNAMICS; PRIORITY JOURNAL; RADIOLIGAND DISSOCIATION; RADIOLOGICAL PARAMETERS; REVIEW;

ALLOSTERIC REGULATION; ANIMALS; ANTIBODY AFFINITY; BINDING, COMPETITIVE; CELL LINE; CELL MEMBRANE; COMPUTER SIMULATION; DRUG DELIVERY SYSTEMS; HUMANS; LIGANDS; MODELS, BIOLOGICAL; PHARMACOKINETICS; PROTEIN BINDING; RADIOLIGAND ASSAY;

EID: 84862847461     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2012.687720     Document Type: Review

References (100)

1. Holford NHG, Sheiner LB. Kinetics of pharmacological response. Pharmacol Ther 1982;16:143-66
2. Eklind-Cervenka M, Benson L, Dahlstrom U, et al. Association of candesartan vs losartan with all-cause mortality in patients with heart failure. J Am Med Assoc 2011;305:175-82
3. Kjeldsen SE, Stalhammar J, Hasvold P, et al. Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. J Hum Hypertens 2010;24:263-73
4. Swinney DC. Biochemical mechanisms of drug action: what does it take for success? Nat Rev Drug Discov 2004;3:801-8 (Pubitemid 39242832)
5. Swinney DC. Biochemical mechanisms of new molecular entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and safety. Curr Top Med Chem 2006;6:461-78
6. Swinney DC. Can binding kinetics translate to a clinically differentiated drug? From theory to practice. Lett Drug Des Discov 2006;3:569-74 (Pubitemid 44544011)
7. Swinney DC. Applications of binding kinetics to drug discovery: translation of binding mechanisms to clinically differentiated therapeutic responses. Int J Pharm Med 2008;22:23-34
8. Swinney DC. The role of binding kinetics in therapeutically useful drug action. Curr Opin Drug Discov Dev 2009;12:31-9
9. Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 2006;5:730-9 (Pubitemid 44323700)
10. Tummino PJ, Copeland RA. Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 2008;47:5481-92 (Pubitemid 351711169)
11. Copeland RA. The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety. Expert Opin Drug Discov 2010;5:305-10
12. Zhang R, Monsma F. The importance of drug-target residence time. Curr Opin Drug Discov Devel 2009;12:488-96
13. Zhang R, Monsma F. Binding kinetics and mechanism of action: toward the discovery and development of better and best in class drugs. Expert Opin Drug Discov 2010;5:1023-9
14. Vauquelin G, Van Liefde I. Slow antagonist dissociation and long-lasting in vivo receptor protection. Trends Pharmacol Sci 2006;27:356-9
15. Vauquelin G. Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence time. Expert Opin Drug Discov 2010;5:927-41
16. Vauquelin G, Charlton S. Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br J Pharmacol 2010;161:488-508
17. Vauquelin G, Bostoen S, Vanderheyden P, Seeman P. Clozapine, atypical antipsychotics and the benefits of fast-off D2 dopamine receptor antagonism. Naunyn Schmiedebergs Arch Pharmacol 2012, published online Feb 14 2012, doi 10.1007/s00210-012-0734-2
18. Vauquelin G. Determination of drug-receptor residence times by radioligand binding and functional assays: experimental strategies and physiological relevance. Med Chem Commun 2012;doi 10.1039/C2MD20015E
19. Dowling MR, Charlton SJ. Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor. Br J Pharmacol 2006;148:1134-42
20. Heise CE, Sullivan S, Crowe PD. Scintillation proximity assay as high-throughput method to identify slowly dissociating nonpeptide ligand binding to the GnRH receptor. J Biomol Screen 2007;12:235-9 (Pubitemid 46364424)
21. Malany S, Hernandez LM, Smith WF, et al. Analytical method for simultaneously measuring ex vivo drug receptor occupancy and dissociation rate: application to (R)-dimethindene occupancy of central histamine H1 receptors. J Recept Signal Transduct Res 2009;29:84-93
22. Packeu A, Wennerberg M, Ballendran A, Vauquelin G. Estimation of the dissociation rate of unlabelled ligand-receptor complexes by competition binding approach. Br J Pharmacol 2010;161:1311-28
23. De Meyts P, Roth J, Neville DM Jr, et al. Insulin interactions with its receptors: experimental evidence for negative cooperativity. Biochem Biophys Res Commun 1973;55:154-61
24. De Meyts P. Insulin and its receptor: structure, function and evolution. Bioessays 2004;26:1351-62 (Pubitemid 39664629)
25. Christopoulos A, Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacol Rev 2002;54:323-74 (Pubitemid 34575719)
26. Christopoulos A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov 2002;1:198-210 (Pubitemid 37361423)
27. Valant C, Robert Lane J, Sexton PM, Christopoulos A. The best of two worlds? Bitopic orthostetic/allosteric ligands of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 2012;52:153-78
28. Kostenis E, Mohr K. Composite action of allosteric modulators on ligand binding. Trends Pharmacol Sci 1996;17:443-4
29. Ellis J. Allosteric binding sites on muscarinic receptors. Drug Dev Res 1997;40:193-204
30. Ellis J, Seidenberg M. Interactions of alcuronium, TMB-8, and other allosteric ligands with muscarinic acetylcholine receptors: studies with chimeric receptors. Mol Pharmacol 2000;58:1451-60
31. Molderings GJ, Menzel S, Kathmann M, et al. Dual interaction of agmatine with the rat alpha2D-adrenoceptor: competitive antagonism and allosteric activation. Br J Pharmacol 2000;130:1706-12 (Pubitemid 30611952)
32. Limbird LE, Lefkowitz RJ. Negative cooperativity among beta-adrenergic receptors in frog erythrocyte membrane. J Biol Chem 1976;251:5007-14
33. De Meyts P, Bianco R, Roth J. Site-site interactions among insulin receptors. Characterization of the negative cooperativity. J Biol Chem 1977;251:1877-88
34. Sutter A, Riopelle RG, Harris-Warrick RM, Shooter EM. Nerve growth factor receptors. Characterization of two distinct classes of binding sites on chick embryo sensory ganglia cells. J Biol Chem 1979;254:5972-82 (Pubitemid 9242473)
35. Springael JY, Le Minh PN, Urizar E, et al. Allosteric modulation of binding properties between units of chemokine receptor homo- and hetero-oligomers. Mol Pharmacol 2006;69:1652-61
36. Szidonya L, Cserzo M, Hunyady L. Dimerization and oligomerization of G-protein-coupled receptors: debated structures with established and emerging functions. J Endocrinol 2008;196:435-53 (Pubitemid 351425500)
37. Berg HC, Purcell EM. Physics of chemoreception. Biophys J 1977;20:193-219
38. Shoup D, Szabo A. Role of diffusion in ligand binding to macromolecules and cell-bound receptors. Biophys J 1982;40:33-9
39. Goldstein B, Posner RG, Torney DC, et al. Competition between solution and cell surface receptors for ligand. Dissociation of hapten bound to surface antibody in the presence of solution antibody. Biophys J 1989;56:955-66
40. Goldstein B, Dembo M. Approximating the effects of diffusion on reversible reactions at the cell surface: ligand-receptor kinetics. Biophys J 1995;68:1222-30
41. Fierens F, Vanderheyden PML, Roggeman C, et al. Distinct binding properties of the AT1 receptor antagonist [3H]candesartan to intact cells and membrane preparations. Biochem Pharmacol 2002;63:1273-9 (Pubitemid 34326471)
42. Silhavy TJ, Szmelcman S, Boos W, Schwartz M. On the significance of the retention of ligand by protein. Proc Natl Acad Sci USA 1975;72:2120-4
43. Spivak CE, Oz M, Beglan CL, Shrager RI. Diffusion delays and unstirred layer effects at monolayer cultures of Chinese hamster ovary cells: Radioligand binding, confocal microscopy, and mathematical simulations. Cell Biochem Biophys 2006;45:43-58 (Pubitemid 43780381)
44. Pike LJ. Lipid rafts: bringing order to chaos. J Lipid Res 2003;44:655-67 (Pubitemid 37279667)
45. Andrews SS. Serial rebinding of ligands to clustered receptors as exemplified by bacterial chemotaxis. Phys Biol 2005;2:111-22 (Pubitemid 40991713)
46. Gopalakrishnan M, Forsten-Williams K, Nugent MA, Tauber UC. Effects of receptor clustering on ligand dissociation kinetics: theory and simulations. Biophys J 2005;89:3686-700
47. Coombs D, Goldstein B. Effects of geometry of the immunological synapse on the delivery of effector molecules. Biophys J 2004;87:2215-20 (Pubitemid 41071324)
48. Perry DC, Mullis KB, Oie S, Sadee W. Opiate antagonist receptor binding in vivo: evidence for a new receptor binding model. Brain Res 1980;199:49-61 (Pubitemid 10052239)
49. Sadee W, Perry DC, Rosenbaum JS, Herz A. [3H]-diprenorphine receptor binding in vivo and in vitro. Eur J Pharmacol 1982;81:431-40 (Pubitemid 12039783)
50. Szczuka A, Packeu A, Wennerberg M, Vauquelin G. Molecular mechanism of the persistent bronchodilatory effect of the partial beta2-adrenoceptor agonist salmeterol. Br J Pharmacol 2009;158:183-94
51. Frost JJ, Wagner HR Jr. Kinetics of binding to opiate receptors in vivo predicted from in vitro parameters. Brain Res 1984;305:1-11 (Pubitemid 14117838)
52. Nieba L, Krebber A, Pluckthun A. Competition BIAcore for measuring true affinities: large differences from values determined from binding kinetics. Anal Biochem 1996;234:155-65 (Pubitemid 26063796)
53. Schuck P, Minton AP. Analysis of mass transport-limited binding kinetics in evanescent wave biosensors. Anal Biochem 1996;240:262-72 (Pubitemid 26304270)
54. Myszka DG, He X, Dembo M, et al. Extending the range of rate constants available from BIACORE: interpreting mass transport-influenced binding data. Biophys J 1998;75:583-94 (Pubitemid 28357501)
55. Abbott AJ, Nelsestuen GL. The collisional limit: an important consideration for membrane-associated enzymes and receptors. FASEB J 1988;2:2858-66
56. Le MT, Pugsley M, Vauquelin G, Van Liefde I. Angiotensin II AT1 antagonism and insurmountability: comparison of olmesartan and telmisartan. Br J Pharmacol 2007;151:952-62 (Pubitemid 47195538)
57. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005;23:1126-36 (Pubitemid 41486394)
58. Steinfeld T, Hughes AD, Klein U, et al. THRX-198321 is a bifunctional muscarinic receptor antagonist and beta2-adrenoceptor agonist (MABA) that binds in a bimodal and multivalent manner. Mol Pharmacol 2011;79:389-99
59. Kaufman EN, Jain RK. Effect of bivalent interaction upon apparent antibody affinity: experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays. Cancer Res 1992;52:4157-67
60. Pluckthun A, Pack P. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology 1997;3:83-105 (Pubitemid 27356788)
61. De Meyts P, Gauguin L, Svendsen AM, et al. Structural basis of allosteric ligand-receptor interactions in the insulin-relaxin peptide family: implications for other receptor tyrosine kinases and G-protein-coupled receptors. Ann NY Acad Sci 2009;1160:45-53
62. De Meyts P. The insulin receptor: a prototype for dimeric, allosteric membrane receptors? Trends Biochem Sci 2008;33:376-84
63. Christopoulos A, Lunzafame A, Ziegler A, Mitchelson F. Kinetic studies of co-operativity at atrial muscarinic M2 receptors with an ''infinite dilution'' procedure. Biochem Pharmacol 1997;53:795-800
64. Packeu A, De Backer J-P, Van Liefde I, et al. Antagonist- dopamine D2L- receptor interactions in intact cells. Biochem Pharmacol 2008;75:2192-203
65. Wennerberg M, Cheng L, Hjorth S, et al. Binding properties of antagonists to cannabinoid receptors in intact cells. Fundam Clin Pharmacol 2010;25:200-10
66. De Meyts P. The structural basis of insulin and insulin-like growth factor- (IGF-I) receptor binding and negative cooperativity, and its relevance to mitogenic versus metabolic signaling. Diabetologia 1994;37:S135-48 (Pubitemid 24288803)
67. Macdonald JL, Pike LJ. Heterogeneity in EGF-binding affinities arises from negative cooper- ativity in an aggregating system. Proc Natl Acad Sci USA 2008;105:112-17
68. De Meyts P, Urso B, Christoffersen CT, Shymko RM. Mechanism of insulin and IGF-I receptor activation and signal transduction specificity. Receptor dimer crosslinking, bell-shaped curves, and sustained versus transient signaling. Ann NY Acad Sci 1995;766:388-401
69. Kiselyov VV, Versteyhe S, Gauguin L, De Meyts P. Harmonic oscillator model of the insulin and IGF1 receptors' allosteric binding and activation. Mol Syst Biol 2009;5:243
70. Knudsen L, De Meyts P, Kiselyov VV. Insight into the molecular basis for the kinetic differences between the two insulin receptor isoforms. Biochem J 2011;440:397-403
71. (Pubitemid 44387610)
72. Copeland RA. Conformational adaptation in drug-target interactions and residence time. Future Med Chem 2011;3:1491-501
73. Bulenger S, Marullo S, Bouvier M. Emerging role of homo- and heterodimerization in G- protein-coupled receptor biosynthesis and maturation. Trends Pharmacol Sci 2005;26:131-7 (Pubitemid 40313592)
74. Pizard A, Machetti J, Allegrini J, et al. Negative cooperativity in the human bradykinin B2 receptor. J Biol Chem 1998;273:1309-15 (Pubitemid 28133646)
75. Springael JY, Urizar E, Costagliola S, et al. Allosteric properties of G protein-coupled receptor oligomers. Pharmacol Ther 2007;115:410-18 (Pubitemid 47362379)
76. Urizar E, Montanelli L, Loy T, et al. Glycoprotein hormone receptors: link between receptor homodimerization and negative cooperativity. EMBO J 2005;24:1954-64 (Pubitemid 40896167)
77. Svendsen AM, Vrecl M, Ellis TM, et al. Cooperative binding of insulin-like peptide 3 to a dimeric relaxin family peptide receptor 2. Endocrinology 2008;149:113-20
78. Kenakin T. Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol Sci 2003;24:346-54 (Pubitemid 37315526)
79. Urban JD, Vargas GA, von Zastrow M, Mailman RB. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 2007;320:1-13 (Pubitemid 46025713)
80. Nygaard R, Frimurer TM, Holst B, et al. Ligand binding and micro-switches in 7TM receptor structures. Trends Pharmacol Sci 2009;30:249-59
81. Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 2009;8:41-54
82. Albizu L, Balestre MN, Breton C, et al. Probing the existence of G protein-coupled receptor dimers by positive and negative ligand-dependent cooperative binding. Mol Pharmacol 2006;70:1783-91
83. El Asmar L, Springael JY, Ballet S, et al. Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers. Mol Pharmacol 2005;67:460-9 (Pubitemid 40216739)
84. Kopelman R. Fractal reaction kinetics. Science 1988;241:1620-6
85. Christensen LLH. Theoretical analysis of protein concentration determination using biosensor technology under conditions of partial mass transport limitation. Anal Biochem 1997;249:153-64 (Pubitemid 27291095)
86. Fujimori K, Covell DC, Fletcher JE, Weinstein JN. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab)2, and Fab in tumors. Cancer Res 1989;49:5656-63 (Pubitemid 19256448)
87. Kenakin TP. Cellular assays as portals to seven-transmembrane receptor-based drug discovery. Nat Rev Drug Discov 2009;8:617-26
88. Hara M, Tozawa F, Itazaki K, et al. Endothelin ET(B) receptors show different binding profiles in intact cells and cell membrane preparations. Eur J Pharmacol 1998;345:339-42 (Pubitemid 28179577)
89. Smith C, Rahman T, Toohey N, et al. Risperidone irreversibly binds to and inactivates the h5-HT7 serotonin receptor. Mol Pharmacol 2006;70:1264-70 (Pubitemid 44435978)
90. Vauquelin G, Packeu A. Ligands, their receptors and plasma membranes. Mol Cell Endocrinol 2009;311:1-10
91. Vauquelin G. Determination of drug-receptor residence times by radioligand binding and functional assays: experimental strategies and physiological relevance. Med Chem Commun 2012, published online March 27 2012, doi:10.1039/C2MD20015E
92. Hrabctova S, Nicholson C. Contribution of dead-space microdomains to tortuosity of brain extracellular space. Neurochem Int 2004;45:467-77 (Pubitemid 38739473)
93. Dokoumetzidis A, Karalis V, Iliadis A, Macheras P. The heterogeneous course of drug transit through the body. Trends Pharmacol Sci 2004;25:140-6 (Pubitemid 38264504)
94. Adam G, Delbruck M. Reduction of dimensionality in biological diffusion processes. In: Rich A, Davidson R, editors, Structural Chemistry and Molecular Biology. W.H. Freeman & Co., San Francisco; 1968. p. 198-215
95. Langlois X, Megens A, Lavreysen H, et al. Pharmacology of JNJ-37822681, specific and fast-dissociating D2 antagonist for the treatment of schizophrenia. Poster presented at the 23nd Congress of European College of Neuropsychopharmacology; Amsterdam 9/2010. Eur Neuropsychopharmacol 2010;20:S502
96. Karbe H, Wienhard K, Haniacher K, et al. Positron emission tomography with [18F]methylspipcronc demonstrates D2 dopamine receptor binding differences of clozapine and haloperidol. J Neural Transm 1991;86:163-73
97. Nordstrom A-L, Farde L, Halldin C. Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology 1992;106:433-8
98. Leysen JE, Gommeren WJ. The dissociation of unlabelled dopamine antagonists and agonists from the dopamine D2-receptor. Implication of an original filter method. J Recept Res 1984;4:817-45 (Pubitemid 15155105)
99. Vauquelin G, Morsing P, Fierens FLP, et al. A two-state receptor model for the interaction between angiotensin II AT1 receptors and their non-peptide antagonists. Biochem Pharmacol 2001;61:277-84 (Pubitemid 32126665)
100. Lazareno S, Birdsall NJM. Detection, quantitation and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol 1995;48:362-78